Your browser doesn't support javascript.
loading
Somatic mutation as a mechanism of Wnt/ß-catenin pathway activation in CLL.
Wang, Lili; Shalek, Alex K; Lawrence, Mike; Ding, Ruihua; Gaublomme, Jellert T; Pochet, Nathalie; Stojanov, Petar; Sougnez, Carrie; Shukla, Sachet A; Stevenson, Kristen E; Zhang, Wandi; Wong, Jessica; Sievers, Quinlan L; MacDonald, Bryan T; Vartanov, Alexander R; Goldstein, Natalie R; Neuberg, Donna; He, Xi; Lander, Eric; Hacohen, Nir; Regev, Aviv; Getz, Gad; Brown, Jennifer R; Park, Hongkun; Wu, Catherine J.
Afiliação
  • Wang L; Cancer Vaccine Center, and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
  • Shalek AK; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA;
  • Lawrence M; Broad Institute, Cambridge, MA;
  • Ding R; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA;
  • Gaublomme JT; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA;
  • Pochet N; Broad Institute, Cambridge, MA;
  • Stojanov P; Broad Institute, Cambridge, MA;
  • Sougnez C; Broad Institute, Cambridge, MA;
  • Shukla SA; Cancer Vaccine Center, and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
  • Stevenson KE; Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA;
  • Zhang W; Cancer Vaccine Center, and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
  • Wong J; Cancer Vaccine Center, and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
  • Sievers QL; Cancer Vaccine Center, and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
  • MacDonald BT; F. M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, MA; Department of Neurology, Harvard Medical School, Boston, MA;
  • Vartanov AR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
  • Goldstein NR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
  • Neuberg D; Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA;
  • He X; F. M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, MA; Department of Neurology, Harvard Medical School, Boston, MA;
  • Lander E; Broad Institute, Cambridge, MA;
  • Hacohen N; Broad Institute, Cambridge, MA; Division of Allergy, Immunology and Rheumatology, Department of Medicine, Massachusetts General Hospital, Boston MA; and.
  • Regev A; Broad Institute, Cambridge, MA;
  • Getz G; Broad Institute, Cambridge, MA;
  • Brown JR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • Park H; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA;
  • Wu CJ; Cancer Vaccine Center, and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Blood ; 124(7): 1089-98, 2014 Aug 14.
Article em En | MEDLINE | ID: mdl-24778153
ABSTRACT
One major goal of cancer genome sequencing is to identify key genes and pathways that drive tumor pathogenesis. Although many studies have identified candidate driver genes based on recurrence of mutations in individual genes, subsets of genes with nonrecurrent mutations may also be defined as putative drivers if they affect a single biological pathway. In this fashion, we previously identified Wnt signaling as significantly mutated through large-scale massively parallel DNA sequencing of chronic lymphocytic leukemia (CLL). Here, we use a novel method of biomolecule delivery, vertical silicon nanowires, to efficiently introduce small interfering RNAs into CLL cells, and interrogate the effects of 8 of 15 mutated Wnt pathway members identified across 91 CLLs. In HEK293T cells, mutations in 2 genes did not generate functional changes, 3 led to dysregulated pathway activation, and 3 led to further activation or loss of repression of pathway activation. Silencing 4 of 8 mutated genes in CLL samples harboring the mutated alleles resulted in reduced viability compared with leukemia samples with wild-type alleles. We demonstrate that somatic mutations in CLL can generate dependence on this pathway for survival. These findings support the notion that nonrecurrent mutations at different nodes of the Wnt pathway can contribute to leukemogenesis.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Transdução de Sinais / Beta Catenina / Via de Sinalização Wnt / Mutação Tipo de estudo: Prognostic_studies Limite: Adult / Humans Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Transdução de Sinais / Beta Catenina / Via de Sinalização Wnt / Mutação Tipo de estudo: Prognostic_studies Limite: Adult / Humans Idioma: En Ano de publicação: 2014 Tipo de documento: Article